Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

Roche has made its case for BTK inhibitor fenebrutinib as a potential new oral therapy for multiple sclerosis, with a phase 2 readout that it says shows significant improvements in disease ...

Roche’s (OTCQX:RHHBY) Genentech subsidiary said the FDA has placed a partial clinical hold on its development program for the drug fenebrutinib in the treatment of multiple sclerosis.

Roche has presented more data from a Phase II study of its Bruton’s tyrosine kinase (BTK) inhibitor after long-term data ...

Research and development expense was $15.5 million for the third quarter of 2024, as compared to $7.6 million for the prior ...

She also notes reassuring results from longer-term trials of fenebrutinib, another BTK inhibitor, in patients with relapsing MS. In all, as these therapies progress through trials, Dr Oh is ...

Roche's key products like Vabysmo, Ocrevus, and Phesgo are performing well. Read why RHHBY stock looks well positioned to ...

Drugmakers had hoped that inhibiting receptor-interacting protein kinase would decrease inflammation and reduce neuronal degeneration in patients with multiple sclerosis and other neurodegenerative co ...

She also notes reassuring results from longer-term trials of fenebrutinib, another BTK inhibitor. The 2024 ECTRIMS Congress featured key presentations on innovative treatments, including the 18 ...

Nov. 6, 2024 — New research is providing a more precise prediction of COVID-19 severity that can be found by looking at autoantibodies in the nasal cavity, leading to more personalized treatment ...

Nov. 1, 2024 — Microplastics have been steadily increasing in freshwater environments for decades and are directly tied to rising global plastic production since the 1950s, according to a new ...

Another Trump term could spur Europe’s efforts to stand on its own, but it is far from clear its leaders will seize the moment this time. By Steven Erlanger Beijing is expecting more ...